Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 132, Issue 1-2, 2012, Pages 176-185

  Badia, Eric ^a,b,c   Docquier, Aurélie ^a,b,c   Busson, Muriel ^a,b,c   Lapierre, Marion ^a,b,c   Pujol, Pascal ^a,b,c,d   Balaguer, Patrick ^a,b,c   Cavailles, Vincent ^a,b,c  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIV MONTPELLIER   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

4 Hydroxytamoxifen; Anti estrogens; BG1 cells; Cancer; Estrogen receptor; Fulvestrant; Ovary

Indexed keywords

AFIMOXIFENE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HISTONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY TEST; DEACETYLATION; DNA METHYLATION; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; OVARIAN NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84864477585     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.05.006     Document Type: Article

References (57)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA: A Cancer Journal for Clinicians 59 4 2009 225 249
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA: A Cancer Journal for Clinicians 62 1 2012 10 29
3. A.J. Ziebarth, C.N. Landen, and R.D. Alvarez Jr. Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges Clinical Obstetrics and Gynecology 55 1 2012 156 172
4. W.P. McGuire, and M. Markman 3rd Primary ovarian cancer chemotherapy: current standards of care British Journal of Cancer 89 Suppl. 3 2003 S3 S8
5. D.H. Suh, K. Kim, and J.W. Kim Major clinical research advances in gynecologic cancer in 2011 Journal of Gynecologic Oncology 23 1 2011 53 64
6. T.J. Shaw, M.K. Senterman, K. Dawson, C.A. Crane, and B.C. Vanderhyden Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer Molecular Therapy 10 6 2004 1032 1042 (Pubitemid 39625247)
7. W.E. Winter, G.L. Maxwell 3rd, C. Tian, J.W. Carlson, R.F. Ozols, P.G. Rose, M. Markman, D.K. Armstrong, F. Muggia, and W.P. McGuire Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study Journal of Clinical Oncology 25 24 2007 3621 3627 (Pubitemid 47372600)
8. J.M. Classe, I. Jaffre, J.S. Frenel, V. Bordes, M. Dejode, F. Dravet, G. Ferron, F. Marchal, D.B. Rigaud, D. Loussouarn, and L. Campion Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases European Journal of Surgical Oncology 37 11 2011 971 977
9. F. Galtier-Dereure, F. Capony, T. Maudelonde, and H. Rochefort Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1 Journal of Clinical Endocrinology and Metabolism 75 6 1992 1497 1502 (Pubitemid 23001410)
10. W.R. Miller, and S.P. Langdon Steroid hormones and cancer: (II) lessons from experimental systems European Journal of Surgical Oncology 23 1 1997 72 83 (Pubitemid 27107497)
11. G.M. Clinton, C. Rougeot, J. Derancourt, P. Roger, A. Defrenne, S. Godyna, W.S. Argraves, and H. Rochefort Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells Proceedings of the National Academy of Sciences of the United States of America 93 1 1996 316 320 (Pubitemid 26038150)
12. S. Cunat, P. Hoffmann, and P. Pujol Estrogens and epithelial ovarian cancer Gynecologic Oncology 94 1 2004 25 32 (Pubitemid 38950494)
13. P. Roger, P. Pujol, A. Lucas, P. Baldet, and H. Rochefort Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors American Journal of Pathology 153 5 1998 1579 1588 (Pubitemid 28509915)
14. B.J. Slotman, and B.R. Rao Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy Anticancer Research 8 3 1988 417 434
15. P. Pujol, J.M. Rey, P. Nirde, P. Roger, M. Gastaldi, F. Laffargue, H. Rochefort, and T. Maudelonde Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis Cancer Research 58 23 1998 5367 5373 (Pubitemid 28551118)
16. J.L. Perez-Gracia, and E.M. Carrasco Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research Gynecologic Oncology 84 2 2002 201 209 (Pubitemid 34139799)
17. M. Markman, K.A. Iseminger, K.D. Hatch, W.T. Creasman, W. Barnes, and B. Dubeshter Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report Gynecologic Oncology 62 1 1996 4 6 (Pubitemid 26234538)
18. C. Trope, C. Marth, and J. Kaern Tamoxifen in the treatment of recurrent ovarian carcinoma European Journal of Cancer 36 Suppl. 4 2000 S59 S61
19. Y.F. Li, W. Hu, S.Q. Fu, J.D. Li, J.H. Liu, and J.J. Kavanagh Aromatase inhibitors in ovarian cancer: is there a role? International Journal of Gynecological Cancer 18 4 2008 600 614 (Pubitemid 352020164)
20. C.A. Papadimitriou, S. Markaki, J. Siapkaras, G. Vlachos, E. Efstathiou, I. Grimani, G. Hamilos, M. Zorzou, and M.A. Dimopoulos Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study Oncology 66 2 2004 112 117 (Pubitemid 38608377)
21. P.A. Argenta, S.G. Thomas, P.L. Judson, L.S. Downs, M.A. Geller Jr., L.F. Carson, A.L. Jonson, and R. Ghebre A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer Gynecologic Oncology 113 2 2009 205 209
22. R. Kothari, P. Argenta, J. Fowler, J. Carter, and W. Shimp Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature Archive of Oncology 18 1-2 2010 32 35
23. B.R. Rao, and B.J. Slotman Endocrine factors in common epithelial ovarian cancer Endocrine Reviews 12 1 1991 14 26
24. K.D. Hatch, J.B. Beecham, J.A. Blessing, and W.T. Creasman Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients Cancer 68 2 1991 269 271
25. R.B. Riggins, R.S. Schrecengost, M.S. Guerrero, and A.H. Bouton Pathways to tamoxifen resistance Cancer Letters 256 1 2007 1 24 (Pubitemid 47333324)
26. R. Clarke, F. Leonessa, J.N. Welch, and T.C. Skaar Cellular and molecular pharmacology of antiestrogen action and resistance Pharmacological Reviews 53 1 2001 25 71 (Pubitemid 32173107)
27. E. Badia, J. Oliva, P. Balaguer, and V. Cavailles Tamoxifen resistance and epigenetic modifications in breast cancer cell lines Current Medicinal Chemistry 14 28 2007 3035 3045
28. R. Zhou, O. Treeck, F. Horn, and O. Ortmann Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells Gynecologic Oncology 96 3 2005 678 683 (Pubitemid 40267684)
29. K.R. Geisinger, T.E. Kute, M.J. Pettenati, C.E. Welander, Y. Dennard, L.A. Collins, and M.E. Berens Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors Cancer 63 2 1989 280 288 (Pubitemid 19035019)
30. C. Donaghue, B.R. Westley, and F.E. May Selective promoter usage of the human estrogen receptor-alpha gene and its regulation by estrogen Molecular Endocrinology 13 11 1999 1934 1950 (Pubitemid 30645266)
31. V. Duong, N. Boulle, S. Daujat, J. Chauvet, S. Bonnet, H. Neel, and V. Cavailles Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents Cancer Research 67 11 2007 5513 5521 (Pubitemid 46997293)
32. G.M. Bernardo, K.L. Lozada, J.D. Miedler, G. Harburg, S.C. Hewitt, J.D. Mosley, A.K. Godwin, K.S. Korach, J.E. Visvader, K.H. Kaestner, F.W. Abdul-Karim, M.M. Montano, and R.A. Keri FOXA1 is an essential determinant of ER alpha expression and mammary ductal morphogenesis Development 137 12 2010 2045 2054
33. J. Eeckhoute, E.K. Keeton, M. Lupien, S.A. Krum, J.S. Carroll, and M. Brown Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer Cancer Research 67 13 2007 6477 6483 (Pubitemid 47037533)
34. M. Kos, G. Reid, S. Denger, and F. Gannon Minireview: genomic organization of the human ER alpha gene promoter region Molecular Endocrinology 15 12 2001 2057 2063 (Pubitemid 33141126)
35. G. Reid, S. Denger, M. Kos, and F. Gannon Human estrogen receptor-alpha: regulation by synthesis, modification and degradation Cellular and Molecular Life Sciences 59 5 2002 821 831 (Pubitemid 34628243)
36. K. Grandien, M. Backdahl, O. Ljunggren, J.A. Gustafsson, and A. Berkenstam Estrogen target tissue determines alternative promoter utilization of the human estrogen receptor gene in osteoblasts and tumor cell lines Endocrinology 136 5 1995 2223 2229
37. R.J. Weigel, D.L. Crooks, J.D. Iglehart, and E.C. deConinck Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma Cell Growth & Differentiation 6 6 1995 707 711
38. G.G. Rao, and D.S. Miller Hormonal therapy in epithelial ovarian cancer Expert Review of Anticancer Therapy 6 1 2006 43 47
39. P. Daniel, S.J. Gaskell, H. Bishop, C. Campbell, and R.I. Nicholson Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma European Journal of Cancer and Clinical Oncology 17 11 1981 1183 1189 (Pubitemid 12247998)
40. J. MacCallum, J. Cummings, J.M. Dixon, and W.R. Miller Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours British Journal of Cancer 82 10 2000 1629 1635 (Pubitemid 30229571)
41. K.R. Coser, B.S. Wittner, N.F. Rosenthal, S.C. Collins, A. Melas, S.L. Smith, C.J. Mahoney, K. Shioda, K.J. Isselbacher, S. Ramaswamy, and T. Shioda Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor Proceedings of the National Academy of Sciences of the United States of America 106 34 2009 14536 14541
42. J.L. Borgna, and H. Rochefort Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues Journal of Biological Chemistry 256 2 1981 859 868 (Pubitemid 11103040)
43. E. Coezy, J.L. Borgna, and H. Rochefort Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Research 42 1 1982 317 323 (Pubitemid 12207285)
44. J.F. Robertson ICI 182,780 (Fulvestrant) - the first oestrogen receptor down-regulator - current clinical data British Journal of Cancer 85 Suppl. 2 2001 11 14 (Pubitemid 33753504)
45. C.K. Osborne, A. Wakeling, and R.I. Nicholson Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action British Journal of Cancer 90 Suppl. 1 2004 S2 S6
46. J.A. Robertson, Y. Zhang, and N.H. Ing ICI 182,780 acts as a partial agonist and antagonist of estradiol effects in specific cells of the sheep uterus Journal of Steroid Biochemistry and Molecular Biology 77 4-5 2001 281 287 (Pubitemid 32703626)
47. H. Varma, and S.E. Conrad Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling Cancer Research 62 14 2002 3985 3991 (Pubitemid 34791064)
48. K. Leblanc, E. Sexton, S. Parent, G. Belanger, M.C. Dery, V. Boucher, and E. Asselin Effects of 4-hydroxytamoxifen, raloxifene and ICI 182,780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens International Journal of Oncology 30 2 2007 477 487
49. R.J. Mehta, R.K. Jain, S. Leung, J. Choo, T. Nielsen, D. Huntsman, H. Nakshatri, and S. Badve FOXA1 is an independent prognostic marker for ER-positive breast cancer Breast Cancer Research and Treatment 131 3 2012 881 890
50. S.H. Park, K.Y. Kim, B.S. An, J.H. Choi, E.B. Jeung, P.C. Leung, and K.C. Choi Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38 Journal of Reproduction and Development 55 1 2009 23 29
51. A.T. Ferguson, R.G. Lapidus, S.B. Baylin, and N.E. Davidson Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression Cancer Research 55 11 1995 2279 2283
52. E. Badia, M.J. Duchesne, S. Fournier-Bidoz, A.E. Simar-Blanchet, B. Terouanne, J.C. Nicolas, and M. Pons Hydroxytamoxifen induces a rapid and irreversible inactivation of an estrogenic response in an MCF-7-derived cell line Cancer Research 54 22 1994 5860 5866 (Pubitemid 24375220)
53. E. Badia, M.J. Duchesne, J.C. Nicolas, and M. Pons Rapid tamoxifen-induced inactivation of an estrogenic response is accompanied by a localized epigenetic modification but not by mutations Breast Cancer Research and Treatment 47 1 1998 71 81 (Pubitemid 28048153)
54. J. Oliva, S. El Messaoudi, F. Pellestor, M. Fuentes, V. Georget, P. Balaguer, V. Cavailles, F. Vignon, and E. Badia Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells FEBS Letters 579 20 2005 4278 4286 (Pubitemid 41116352)
55. M.A. Tessel, N.L. Krett, and S.T. Rosen Steroid receptor and microRNA regulation in cancer Current Opinion in Oncology 22 6 2010 592 597
56. B.D. Adams, H. Furneaux, and B.A. White The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines Molecular Endocrinology 21 5 2007 1132 1147 (Pubitemid 46984764)
57. X. Rao, G. Di Leva, M. Li, F. Fang, C. Devlin, C. Hartman-Frey, M.E. Burow, M. Ivan, C.M. Croce, and K.P. Nephew MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways Oncogene 30 9 2011 1082 1097